Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Is there any contraindication for a patient receiving omalizumab for treatment of her lung aspergillosis to receive adjuvant breast radiotherapy?
Related Questions
When treating APBI with the Florence regimen, are you using daily or every other day fractionation?
Would you omit post-lumpectomy radiotherapy for high clinical risk, but low molecular risk DCIS?
Would you offer a patient with “good-risk” DCIS and an elevated DCISionRT score APBI or WBI?
Would you omit radiation for an elderly woman with bilateral breast cancers (both early-stage disease and ER+/PR+/HER2 negative) who otherwise meets the criteria for endocrine therapy alone?
Are you comfortable combining palliative radiotherapy with capivasertib/fulvestrant?
When should the dissected axilla (levels I-II) be included when delivering RNI?
Can a patient receiving post-mastectomy radiation therapy be treated concurrently with total body UVA or UVB light therapy for psoriasis?
Would you consider omitting PMRT in cT3N0 triple negative breast cancer with a pCR?
How would you manage a patient with micrometastatic node positive tumor post mastectomy (no neoadjuvant chemotherapy)?
Would you ever considering de-escalating therapy in any way for women with inflammatory breast cancer who had a complete pathologic response after surgery?
